



28 September 2023

**LungLife AI, Inc.**  
(the “Company” or “LungLife”)

**Clinical validation study update**

LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for the early detection of lung cancer, provides an update on the Company’s clinical validation study for its LungLB® test.

As stated in the Company’s [half-year report](#) on 8 August 2023, LungLife is currently focussed on preparing data from the clinical validation study for detailed analysis, which was expected to be concluded by the end of September 2023. Due to delays in the provision of data from study sites, full database lock, and the consequent knock-on impact on ability to analyse the data we now expect this to be concluded in Q4 2023.

**For further information please contact:**

**LungLife AI, Inc.**  
Paul Pagano, CEO  
David Anderson, CFO

[www.lunglifeai.com](http://www.lunglifeai.com)  
Via Walbrook PR

**Investec Bank plc (Nominated Adviser & Joint Broker)**  
Virginia Bull / Cameron MacRitchie / Lydia Zychowska

Tel: +44 (0)20 7597 5970

**Goodbody (Joint Broker)**  
Tom Nicholson / Stephen Kane

Tel: +44 (0) 20 3841 6202 / +353 (1) 667 0420

**Walbrook PR Limited**  
Paul McManus / Alice Woodings / Phillip Marriage

Tel: +44 (0)20 7933 8780 or [LungLifeAI@walbrookpr.com](mailto:LungLifeAI@walbrookpr.com)  
Mob: 07980 541 893 / 07407 804 654 / 07867 984 082

**About LungLife**

LungLife AI is a developer of clinical diagnostic solutions designed to make a significant impact in the early detection of lung cancer, the deadliest cancer globally. Using a minimally invasive blood draw, the Company's LungLB® test is designed to deliver additional information to clinicians who are evaluating indeterminate lung nodules. For more information visit [www.lunglifeai.com](http://www.lunglifeai.com)